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BACKGROUND: Vulvar squamous cell carcinoma (SCC) originates the following two pathways, related to differentiated (d) vulvar
intraepithelial neoplasia (VIN) or to human papillomavirus (HPV)-related usual (u) VIN. Multicentric HPV infections (cervix, vagina
and vulva) are common. We hypothesise that patients with a uVIN-related vulvar SCC more often have cervical high-grade
squamous intraepithelial lesions (HSILs) compared with women with dVIN-related vulvar SCC.
METHODS: All vulvar SCCs (201) were classified to be dVIN- (n¼164) or uVIN related (n¼37). Data with regard to the smear
history and cervical histology were retrieved from PALGA, the nationwide Netherlands database of histo- and cytopathology. For
HSIL cervical smears of which histology was taken, HPV DNA analysis on both the vulvar and cervical specimens was performed.
RESULTS: At least one smear was available in 145 (72%) of the 201 patients. Patients with a uVIN-related vulvar SCC more often had
an HSIL compared with patients with a dVIN-related SCC (35 vs 2%, Po0.001). A total of 10 of the 13 HSILs were histologically
assessed and identical HPV types were found in the vulva and cervix.
CONCLUSION: These data emphasise the necessity to differentiate between dVIN- and uVIN-related vulvar tumours and to examine
the entire lower female ano-genital tract once an uVIN-related lesion is found.
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Vulvar squamous cell carcinoma (SCC) accounts for 3–5% of all
gynaecological malignancies and originates following two separate
pathways. One type of vulvar SCC, accounting for B80%, occurs
mainly in older patients and is mostly of the keratinising type,
associated with lichen sclerosus (LS) and/or differentiated vulvar
intraepithelial neoplasia (dVIN) as premalignant lesions. The other
type, accounting for B20%, is human papillomavirus (HPV)
related, occurs in younger patients, and has usual VIN (uVIN) as
premalignancy (van der Avoort et al, 2006). Recently, we found
that uVIN-associated vulvar SCC patients had a significantly better
disease-free survival than dVIN-associated vulvar SCC patients
(van de Nieuwenhof et al, 2009b). The majority of uVIN-related
vulvar SCCs are caused by HPVs 16, 18 and 33 (Toki et al, 1991;
Hording et al, 1994; Iwasawa et al, 1997; Pinto et al, 2004; Hampl
et al, 2006). The development of uVIN and vulvar SCC mirrors that
of cervical intraepithelial neoplasia (CIN) and cervical SCC, the
latter caused by (high-risk human papillomavirus) hrHPV in
nearly 100% of the cases (Walboomers et al, 1999; Bekkers et al,
2004). A subdivision on the basis of hrHPV DNA presence between
the two types of vulvar SCC does not separate the two different
pathways accurately. High-risk HPV presence does not per se
indicate a causal role in the carcinogenesis and may represent a
non-significant or transient infection. A better method of
subdividing the two types of vulvar SCC is on the basis of the
histology of the adjacent VIN lesion (Vilmer et al, 1998; Rouzier
et al, 2001; van de Nieuwenhof et al, 2009b).
Multicentric HPV infections affecting vulva, cervix, vagina and
anus simultaneously have been described in several studies
(Adamek et al, 2003; Bekkers et al, 2004; Lara-Torre and Perlman,
2004; Feng and Kiviat, 2005; Goffin et al, 2006; Hampl et al, 2007),
making a thorough examination of the entire lower female ano-
genital tract obligatory. A decreased immune response to hrHPV
has been suggested to be the cause of these multicentric hrHPV
infections (Hampl et al, 2007), although it is also possible that HPV
affects cervix and vulva consecutively.
In this study, we investigate whether patients with uVIN-related
vulvar SCCs more often have abnormal cervical smears and/or
histologically confirmed cervical (pre)malignancies compared with
women with dVIN/LS-related vulvar SCC. Moreover, we investigate
which hrHPV types play a role in either uVIN-related vulvar SCCs
and cervical (pre)malignancies.
PATIENTS AND METHODS
Between 1988 and 2007, 209 consecutive patients were treated for
their primary invasive or recurrent SCC of the vulva at the
Radboud University Nijmegen Medical Centre, The Netherlands.
Received 20 February 2009; revised 7 May 2009; accepted 12 May 2009;
published online 9 June 2009
*Correspondence: Dr RP de Bie; E-mail: R.deBie@obgyn.umcn.nl
4These authors equally contributed to this work
British Journal of Cancer (2009) 101, 27–31
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sData were stored in a database. All histopathological slides were
revised to classify the adjacent lesion as uVIN, LS and/or dVIN, to
categorise the vulvar cancers into uVIN- or dVIN related (Park
et al, 1991; Wilkinson, 1992; Carlson et al, 1998; Yang and Hart,
2000; Chiesa-Vottero et al, 2006). In eight cases, the subdivision
was impossible because the diagnosis of the type of VIN lesion was
uncertain because of massive intraepithelial inflammation, epi-
thelial destruction due to massive ulceration or because the
required tissue was not available. The remaining 201 patients
constituted the study population.
Cervical smears
Data with regard to the smear history and cervical histology were
retrieved from PALGA, the nationwide Netherlands database of
histo- and cytopathology. This database has had national coverage
from 1991 onwards, showing all surgical specimens and cervical
smears ever taken from each patient, both by the general
practitioner and medical specialists (Casparie et al, 2007). The
cervical histology and smear history were available for all the 201
patients.
Cervical smears were subdivided into smears taken more than 1
year before the diagnosis of vulvar SCC; smears taken within 1 year
before the diagnosis of vulvar SCC; and smears taken after primary
treatment for vulvar SCC.
In case multiple smears were taken during the study period, the
most severe lesion was used for the analysis. Histology was
preferred above cytology.
Histology of adjacent VIN lesion
A subdivision on the basis of the histology of the adjacent VIN
lesion (we adopted the new ISSVD Classification (Sideri et al,
2005)) was considered the most appropriate method to subdivide
the vulvar SCCs into a pathway (van de Nieuwenhof et al, 2009b).
Every original surgical specimen was revised for the presence
of LS and/or VIN lesions, based on the current histopathological
characteristics (Hart, 2001). If a patient had a high-grade
squamous intraepithelial lesion (HSIL) resulting in a histological
diagnosis, these specimens were retrieved in order to perform HPV
DNA analysis on both the vulvar and cervical specimens. The
presence of HPV was determined and genotyping was performed
without the knowledge of patients’ correlating tissues.
SPF10-INNO LiPA HPV detection and genotyping
DNA was isolated from formalin-fixed paraffin-embedded tissue
sections (6mm) with the EZ1 robot (with the DNA tissue kit of
Qiagen Inc, Valencia, CA, USA) according to the standard
procedures and used for PCR analysis. A negative water control
was included with each batch of 10 samples. Broad-spectrum HPV
DNA amplification was performed using a short PCR fragment
assay (HPV SPF10 Line Blot 25, Labo Bio-medical products BV
Rijswijk, The Netherlands). This assay amplifies a 65-bp fragment
of the L1 open reading frame, and allows detection of a broad
range of high-risk (hr), low-risk (lr) and possible hrHPV
genotypes (Kleter et al, 1998; Melchers et al, 1999). Twenty-eight
oligonucleotide probes that recognise 25 different types were tailed
with poly(dT) and immobilised as parallel lines to membrane
strips (Labo Bio-medical products BV Rijswijk, the Netherlands).
The HPV genotypes detectable are hrHPVs 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, and 68/73 and two probable hrHPV types (53
and 66), and lrHPV genotypes 6 and 11, and so on. The HPV
genotyping assay was performed as described earlier (van Hamont
et al, 2006). The line probe assay (LiPA) strips were visually
inspected, and interpreted using the provided reference guide. As a
quality control for the presence of DNA and absence of PCR
inhibitors in the isolated material a b-globin PCR was performed,
as described by Snijders et al (2006). For the real-time PCR
method, 5ml of DNA was used.
Statistical methods
The Kolmogorov–Smirnov test was used to evaluate whether the
variables age, year of diagnosis, and first-line treatment of the two
groups had a normal distribution. As the variables were not all
normally distributed, all analyses were performed using non-
parametrical tests. For analytical purposes, the histology and pap
smears were subdivided into the Bethesda nomenclature, low-
grade squamous intraepithelial lesions (LSILs) or less, and at least
an HSIL. Fisher’s exact test was used to compare hrHPV presence
in uVIN and dVIN lesions adjacent to vulvar SCCs and to compare
the different groups of vulvar SCC patients with respect to cervical
abnormalities. P-values presented are two-tailed and the results
were statistically significant at Po0.05.
RESULTS
The data of a total number of 201 patients were analysed. The
median age of the patients at diagnosis was 71 years (range
30–92). The median age at diagnosis of the dVIN/LS-related
pathway group (72 years, range 31–92) and the uVIN-related
pathway group (54 years, range 30–88) differed significantly
(Po0.001).
Histology of the adjacent VIN lesion and HPV
Histopathological review of the VIN lesion directly adjacent to the
tumour led to a total number of 37 (18%) tumours that were
considered to follow the uVIN-related pathway, and 164 (82%) that
were considered to follow the dVIN/LS-related pathway. Of the 164
dVIN/LS-related tumours, 54 (33%) tissues showed solitary dVIN,
22 (13%) tissues showed solitary LS and 88 (54%) tissues showed
dVIN in combination with LS, as surrounding lesions. Of 168
tumours (32 uVIN and 136 dVIN/LS), both histology of the
adjacent VIN lesion and HPV presence and typing could be
performed. Of the uVIN-related tumours, 27 of the 32 (84.4%) were
found hrHPV positive and 13 out of 136 (9.6%) of the dVIN/LS-
related tumours were found hrHPV positive (Table 1). For the
uVIN-related pathway, high-risk HPV types predominated, in
particular types 16 (62%) and 33 (17%). The other 21% were
caused by types 18, 52 and 58. Of the 13 hrHPV-positive tumours
in the dVIN-related pathway, six tumours were found to be HPV
16 positive (46%) and the other seven were found to be HPV 18,
33, 52 or 53 positive.
Smear histories
From 28% of the patients, no cervical smears or cervical biopsies
had ever been taken. These patients had a median follow-up after
their vulvar SCC of 8 years (range 1–20), without any clinical
indication of cervical disease; 87% of these women were older than
Table 1 Distribution of high-risk human papillomavirus (hrHPV) in
relation to the pathological pathway in 168 tissues of which both HPV
DNA analysis and pathological pathway was available, Po0.001
hrHPV+ hrHPV  Total
uVIN 27 5 32
dVIN/LS 13 123 136
Total 40 128 168
dVIN¼differentiated vulvar intraepithelial neoplasia; LS¼lichen sclerosus;
uVIN¼usual vulvar intraepithelial neoplasia
Risk of cervical abnormalities in vulvar cancer patients
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s55 years of age from the start of the national screening program for
cervical cancer in 1988, as a result of which they exceeded the age
limit to be invited. Of the 145 patients from whom at least one
smear was available, the most severe lesion was taken: of these
patients, 9.0% (n¼13) had a smear indicating an HSIL. Patients
with uVIN-related tumours had significantly more cervical smears
indicating an HSIL, compared with patients with LS/dVIN-related
tumours, 11 of 31 (35%) and 2 of 114 (2%) (Po0.001), respectively
(Table 2).
HSIL on cytology, histologically assessed
Histological specimens were examined after an HSIL smear in 10
of the 13 patients: in two cases there was a CIN I lesion, seven were
CIN III lesions and one seemed to be an invasive cervical SCC.
Chronologically, in five cases the CIN lesion was diagnosed before
the vulvar SCC with an interval in time from 5 to 13 years (cases 2;
3; 7; 8; and 10); in four cases the CIN lesion was diagnosed
simultaneously with the vulvar SCC (cases 1; 4; 6; and 9); and
in one case the CIN lesion was diagnosed 6 years after the vulvar
SCC (case 5).
Three patients with HSIL on cytology had, remarkably, no
histological follow up. One patient died on account of a vulvar
recurrence soon after the HSIL was diagnosed. One had a
cytological follow up with normalisation of the smears in 5 years
without interference of biopsies or excisions. The other particular
patient was diagnosed with a vulvar SCC in 2004 and simulta-
neously had a HSIL on cervical cytology without further cervical
follow up. A total of 9 of the 10 histologically confirmed tumours
showed uVIN in the surrounding tissue and were HPV DNA
positive. The one that showed dVIN in the surrounding tissue was
HPV DNA negative. A cervical lesion of one patient showed
negative b-globin after DNA extraction. In all tissues of the other
eight patients, the same HPV types were found in both the vulvar
and cervical specimens (Table 3).
DISCUSSION
Our study on a large group of patients with vulvar SCCs (201
cases), with regard to cervical (pre)malignancies, showed that 9%
of all patients with available cytology of the cervix had a smear
suggestive for a HSIL. Divided between the two pathways, 35% of
the patients with uVIN-related vulvar SCCs had a smear suggestive
for a HSIL, compared with only 2% of patients whose vulvar SCC
was dVIN related (Po0.001). For uVIN-related SCCs, this is a
more than 10-fold incidence compared with the overall incidence
of a HSIL in The Netherlands (Vereniging Integrale Kankercentra,
2009). In 19% (n¼7) of the total 37 patients with a uVIN-related
vulvar SCC, a histologically proven cervical HSIL or SCC was
found during a follow up of 20 years. Moreover, all of these uVIN-
related vulvar SCCs and cervical lesions in the same patient
showed the identical hrHPV type. These identical hrHPV types
were seen in vulvar SCCs and cervical lesions even after an interval
of more than 10 years. This may be one long-standing infection or
a new infection with the exact same type of virus. Particularly as
less common types were found as well, a long-standing infection is
most likely. Furthermore, if a patient’s immune system is not able
to clear a hrHPV infection, that patient is thought to be more
prone to develop multicentric (pre)malignancies. In most cases,
the cervical lesion preceded the vulvar SCC, although vulvar SCCs
preceding cervical lesions were seen as well. The difficulty is
whether the date of diagnosis accurately reflects the origin of the
lesions. It may well be possible that these lesions had initially been
asymptomatic and present for a longer period before diagnosis.
Our data suggest that the identical long-standing hrHPV infection
is causing these multicentric (pre)malignancies. This emphasises
the concept that a patient with a hrHPV-related ano-genital
(pre)malignancy is at a higher risk to develop another hrHPV-
related (pre)malignancy. We previously reported that 41% of uVIN
patients had a past, simultaneous or future HPV-induced cervical,
vaginal or anal lesion (van de Nieuwenhof et al, 2009a).
Unfortunately, in this cohort of vulvar SCC patients, we were not
able to retrieve data about other multicentric sites of the lower
female ano-genital tract prone to hrHPV infection. This higher risk
to develop other hrHPV-related (pre)malignancies obliges us to
differentiate between dVIN and uVIN lesions followed by a precise
examination of the entire lower female ano-genital tract in case of a
vulvar carcinoma, especially in case of a tumour from the uVIN-
related pathway.
In general, several studies showed that patients with uVIN-
related vulvar SCC are younger than dVIN/LS-related vulvar SCC
patients (Hording et al, 1994; Hampl et al, 2006; Hoevenaars et al,
2008; van de Nieuwenhof et al, 2009a). In our study, we confirm
this observation with a significant difference in age distribution
between the two different groups, 72 years for the hrHPV-
unrelated and 54 years for the hrHPV-related groups (Po0.001).
If we compare the median age for cervical SCC, which is caused
by hrHPV in nearly 100% of the cases, with the median age for
uVIN/hrHPV-related vulvar SCC, we find a comparable age, 51
Table 2 Total cervical specimens/smears of patients with vulvar
squamous cell carcinoma, subdivided between two different pathways,
related to LS/dVIN, or uVIN, Po0.001
LS, dVIN-related pathway uVIN-related pathway
pLSIL 112 (98%) 20 (65%)
XHSIL 2 (2%) 11 (35%)
dVIN¼differentiated vulvar intraepithelial neoplasia; HSIL¼high-grade squamous
intraepithelial lesion; LS¼lichen sclerosus; LSIL¼low-grade squamous intraepithelial
lesion; uVIN¼usual vulvar intraepithelial neoplasia.
Table 3 Ten cases of vulvar SCCs and cytologically a high-grade
squamous intraepithelial lesion of the cervix with histological correlating
lesion and HPV types
Case
Adjacent
lesion Year Age Type of tumour HPV
1 uVIN 2007 65 Vulvar SCC 16
2007 65 Cervical SCC 16
2 uVIN 1990 34 VIN III 33
1990 34 Cervical carcinoma in situ 33
uVIN 2003 47 Vulvar SCC 33
3 1990 38 CIN III 16
uVIN 2003 51 Vulvar SCC 16
4 uVIN 1998 37 Vulvar SCC 16
1998 37 CIN III 16
uVIN 2006 45 Vulvar SCC 16
5 uVIN 1999 45 Vulvar SCC 16,52
2005 51 CIN III 52
6 uVIN 2004 37 Vulvar SCC 16,18,54
2004 37 CIN III 16
2007 40 CIN III 16
7 1986 37 CIN III 58
uVIN 1992 43 Vulvar SCC 58
8 1997 48 CIN I 16
uVIN 2002 53 Vulvar SCC 16,58
9 uVIN 2004 58 Vulvar SCC 16
2004 58 CIN I b-Globin
negative
10 1994 49 CIN III 31
LS+dVIN 2005 60 Vulvar SCC Negative
CIN¼cervical intraepithelial neoplasia; dVIN¼differentiated vulvar intraepithelial
neoplasia; HPV¼human papillomavirus; LS¼lichen sclerosus; SCCs¼squamous cell
carcinomas; uVIN¼usual vulvar intraepithelial neoplasia. Bold values indicate identical
hrHPV types.
Risk of cervical abnormalities in vulvar cancer patients
RP de Bie et al
29
British Journal of Cancer (2009) 101(1), 27–31 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
syears and 54 years, respectively (Hacker, 2000). This may suggest
that a hrHPV infection brings about an earlier age of onset of
uVIN-related vulvar carcinogenesis compared with the dVIN-
related vulvar carcinogenesis. In this study, cervical (pre)ma-
lignancies with compatible hrHPV types were diagnosed as well
before, simultaneous as after a uVIN-related vulvar SCC.
We found a hrHPV prevalence of 23.4% for vulvar SCC in
general. The percentage of hrHPV DNA-positive vulvar SCC
(23.4%) is slightly higher than the percentage of tumours with
adjacent uVIN (18.4%). These findings confirm that not all
hrHPV infections finally lead to vulvar SCC. As hrHPV often
resolves spontaneously, most likely these five percent additional
infections were transient infections, yet to be cleared.
Of the 201 patients, in 56 cases (28%) no cervical smear
information was available: this may be because of the limitation in
coverage of the PALGA database (national coverage from 1991
onwards) or because of the fact that these women never had a
cervical smear taken. Worth mentioning is that 87% of these
women exceeded the age limit to be invited for the national
screening program for cervical cancer. Still, at diagnosis, in 105 of
the 201 (52%) cases no cervical smear was taken around the
diagnosis of the vulvar SCC. Approximately one-fifth of the vulvar
SCCs is uVIN related, and simultaneous cervical and vulvar
infections have previously been described (Adamek et al, 2003;
Lara-Torre and Perlman, 2004; Feng and Kiviat, 2005; Goffin et al,
2006). Therefore, a cervical smear should always be taken during
the diagnostic process of patients with a uVIN-related vulvar SCC.
During the studied period (1988–2007), the role of hrHPV became
more evident. In this study, for all patients diagnosed after 2002,
a cervical smear was taken. This suggests that the cervical smear is
now more embedded in the diagnostic routine of vulvar SCC. Our
results show that it is important not to overlook or underestimate
the possibility of a multicentric HPV infection, causing both
cervical and vulvar (pre)malignancies. Although there is no
evidence, probably because of the low number of patients that
developed a HSIL lesion after vulvar SCC, we would suggest: all
vulvar SCC patients have a cervical smear during the diagnostic
process of their vulvar SCC; for uVIN-associated vulvar SCC
patients a 2-yearly cervical smear should be performed during
follow up.
In conclusion, patients with a uVIN-related vulvar SCC have an
increased incidence of cervical (pre)malignancies with identical
hrHPV types in both cervical and vulvar (pre)malignancies. This
points to the multicentric development of (pre)malignancies and
emphasises the necessity to differentiate between dVIN- and
uVIN-related vulvar tumours. The examination of the entire lower
female ano-genital tract in case of a hrHPV-related vulvar lesion
should therefore be obligatory.
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